Browse
related articles
New medical product development centre opens in Jordan
- Jordan: Thursday, October 30 - 2008 at 08:59
The new Philadelphia Biological and Medical Product Development Centre is to open today in Amman, Jordan. The Centre will be the only healthcare product development hub worldwide that provides preclinical evaluation, full-service clinical research, core lab facilities, as well as cell engineering and culturing, according to a press release. Peggy Farley, the Centre's Chairperson, said the centre will place the Middle East firmly on the map as a global medical technology leader. Farley is also co-founder of the Ascent Medical Technology Funds, including Fund II which is the financial instrument providing the funding for the project. Recently, the Centre successfully carried out a Bioheart Inc sponsored study to support the treatment of potentially life-threatening, heart-related aliments that saw positive results of a pre-clinical study of the Adipose-Derived Stem Cells (ADSCs) therapy study for heart patients.
Related Content
Article Options
Jeff Florian, Senior ReporterThursday, October 30 - 2008 at 08:59 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
Disclaimer »
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.
For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions
